-
Something wrong with this record ?
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
T. Buchler, M. Kopecka, A. Zemankova, M. Wiesnerová, E. Streckova, A. Rozsypalova, B. Melichar, A. Poprach, I. Richter
Language English Country France
Document type Journal Article
NLK
ProQuest Central
from 2006-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2006-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2006-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2006-01-01 to 1 year ago
Family Health Database (ProQuest)
from 2006-01-01 to 1 year ago
- MeSH
- Anilides pharmacology therapeutic use MeSH
- Adult MeSH
- Carcinoma, Renal Cell complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Pyridines pharmacology therapeutic use MeSH
- Sarcopenia drug therapy etiology pathology MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. OBJECTIVE: To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. PATIENTS AND METHODS: Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra. RESULTS: The median muscle mass index at CT1 and CT2 was 52.2 cm2/m2 (range 33.0-69.2 cm2/m2) and 49.1 cm2/m2 (range 33.1-68.2 cm2/m2), respectively. Sarcopenia was initially present in 13 (44.8%) patients. The mean muscle mass change between CT1 and CT2 was - 2.2 cm2/m2 (range - 10.1 to + 4.8cm2/m2). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-90) versus 79.8% (95% CI 62.1-90.6) in others (p = 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. CONCLUSIONS: Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.
Department of Oncology Liberec District Hospital Liberec Czech Republic
Department of Oncology Palacky University Medical and Teaching Hospital Olomouc Czech Republic
Institute of Biostatistics and Analysis Ltd Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004846
- 003
- CZ-PrNML
- 005
- 20220127144926.0
- 007
- ta
- 008
- 220113s2020 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11523-020-00744-8 $2 doi
- 035 __
- $a (PubMed)32748047
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Videnska 800, 140 59, Prague, Czech Republic. tomas.buchler@ftn.cz
- 245 10
- $a Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib / $c T. Buchler, M. Kopecka, A. Zemankova, M. Wiesnerová, E. Streckova, A. Rozsypalova, B. Melichar, A. Poprach, I. Richter
- 520 9_
- $a BACKGROUND: Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. OBJECTIVE: To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. PATIENTS AND METHODS: Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra. RESULTS: The median muscle mass index at CT1 and CT2 was 52.2 cm2/m2 (range 33.0-69.2 cm2/m2) and 49.1 cm2/m2 (range 33.1-68.2 cm2/m2), respectively. Sarcopenia was initially present in 13 (44.8%) patients. The mean muscle mass change between CT1 and CT2 was - 2.2 cm2/m2 (range - 10.1 to + 4.8cm2/m2). Six-month progression-free survival (PFS) was significantly shorter in patients with at least 10% muscle loss, reaching 50% (95% CI 9.9-90) versus 79.8% (95% CI 62.1-90.6) in others (p = 0.022). The presence of initial sarcopenia was not associated with grade 3-4 toxicity, which was reported in six (46.2%) and seven (46.7%) patients with and without sarcopenia, respectively. CONCLUSIONS: Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a anilidy $x farmakologie $x terapeutické užití $7 D000813
- 650 _2
- $a karcinom z renálních buněk $x komplikace $7 D002292
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a pyridiny $x farmakologie $x terapeutické užití $7 D011725
- 650 _2
- $a sarkopenie $x farmakoterapie $x etiologie $x patologie $7 D055948
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kopecka, Marie $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Videnska 800, 140 59, Prague, Czech Republic
- 700 1_
- $a Zemankova, Anezka $u Department of Oncology, Palacky University Medical and Teaching Hospital, Olomouc, Czech Republic
- 700 1_
- $a Wiesnerová, Markéta $u Institute of Biostatistics and Analysis Ltd, Brno, Czech Republic
- 700 1_
- $a Streckova, Eva $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Videnska 800, 140 59, Prague, Czech Republic
- 700 1_
- $a Rozsypalova, Aneta $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Videnska 800, 140 59, Prague, Czech Republic
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical and Teaching Hospital, Olomouc, Czech Republic
- 700 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
- 700 1_
- $a Richter, Igor $u Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Videnska 800, 140 59, Prague, Czech Republic $u Department of Oncology, Liberec District Hospital, Liberec, Czech Republic
- 773 0_
- $w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 15, č. 5 (2020), s. 673-679
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32748047 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127144923 $b ABA008
- 999 __
- $a ok $b bmc $g 1752141 $s 1155995
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 15 $c 5 $d 673-679 $e - $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
- LZP __
- $a Pubmed-20220113
